Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10421540 | 1.00 | USP2 (0.74) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL10420143 | 1.00 | USP2 (0.74) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL10421538 | 1.00 | USP2 (0.74) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL10421558 | 1.00 | USP2 (0.74) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL3680037 | 0.97 | USP2 (0.79) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL10421556 | 0.97 | USP2 (0.79) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL10420970 | 0.95 | USP2 (0.77) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL13299401 | 0.93 | USP2 (0.80) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL18301311 | 0.93 | USP2 (0.80) | USP2HTTPLA2G2CLPAR1LPAR3 | |
| SCHEMBL13299397 | 0.92 | USP2 (0.77) | USP2HTTPLA2G2CLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4948588-A | ETHER DERIVATIVES OF GLYCEROLS OR POLYGLYCEROLS | KAO CORPORATION (JP) | 1990-08-14 | — | — | US | claimed |
| US-4859696-A | Precutaneous absorption accelerator and preparation containing same | KAO CORPORATION (JP) | 1989-08-22 | — | — | US | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119139479-A | Compositions comprising taxane nanoparticles and uses thereof | DFB索里亚有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118948828-A | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118649239-A | Topical delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | 克里蒂泰克公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12070503-B2 | Transdermal carrier | DYVE BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-114588270-B | Compositions comprising taxane nanoparticles and uses thereof | DFB索里亚有限责任公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-110636833-B | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-10555898-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| CN-110636833-A | Topical therapy using taxane nanoparticles for the treatment of skin malignancies | DFB索里亚有限责任公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190201327-A1 | TOPICAL APPLICATIONS OF WITHAFERIN A | Ampersand Biopharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190134219-A1 | INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASES | Ampersand Biopharmaceuticals, Inc. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20170266289-A1 | TOPICAL FORMULATION | ABBVIE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2407454-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-4948588-A | ETHER DERIVATIVES OF GLYCEROLS OR POLYGLYCEROLS | KAO CORPORATION (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4859696-A | Precutaneous absorption accelerator and preparation containing same | KAO CORPORATION (JP) | 1989-08-22 | — | — | US | disclosed |
| EP-0162239-A1 | Percutaneous absorption accelerator and preparation containing same | Kao Corporation (JP) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | USP2 2648/4885HTT 3496/4885PLA2G2C 197/4885 |
| US-20170266289-A1 | TOPICAL FORMULATION | TSLP, CYP51A1, CYP17A1 | USP2 1926/4885HTT 2584/4885PLA2G2C 1593/4885 |
| US-12070503-B2 | Transdermal carrier | NACA, ETF1, SUCLG1 | USP2 2924/4885HTT 365/4885PLA2G2C 3503/4885 |
| US-10555898-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | USP2 3556/4885HTT 4095/4885PLA2G2C 2546/4885 |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | USP2 2648/4885HTT 3496/4885PLA2G2C 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.